Literature DB >> 28008201

Active brain changes after initiating fingolimod therapy in multiple sclerosis patients using individual voxel-based analyses for diffusion tensor imaging.

Joe Senda1, Hirohisa Watanabe2, Kuniyuki Endo3, Keizo Yasui4, Yasuhiro Hawsegawa4, Noritaka Yoneyama3, Takashi Tsuboi3, Kazuhiro Hara3, Mizuki Ito3, Naoki Atsuta3, Bagarinao Epifanio5, Masahisa Katsuno3, Shinji Naganawa6, Gen Sobue7.   

Abstract

Voxel-based analysis (VBA) of diffusion tensor images (DTI) and voxel-based morphometry (VBM) in patients with multiple sclerosis (MS) can sensitively detect occult tissue damage that underlies pathological changes in the brain. In the present study, both at the start of fingolimod and post-four months clinical remission, we assessed four patients with MS who were evaluated with VBA of DTI, VBM, and fluid-attenuated inversion recovery (FLAIR). DTI images for all four patients showed widespread areas of increased mean diffusivity (MD) and decreased fractional anisotropy (FA) that were beyond the high-intensity signal areas across images. After four months of continuous fingolimod therapy, DTI abnormalities progressed; in particular, MD was significantly increased, while brain volume and high-intensity signals were unchanged. These findings suggest that VBA of DTI (e.g., MD) may help assess MS demyelination as neuroinflammatory conditions, even though clinical manifestations of MS appear to be in complete remission during fingolimod.

Entities:  

Keywords:  diffusion tensor imaging (DTI); fingolimod; fluid-attenuated inversion recovery (FLAIR) high-intensity signals.; multiple sclerosis (MS); voxel based morphometry (VBM)

Year:  2016        PMID: 28008201      PMCID: PMC5159471          DOI: 10.18999/nagjms.78.4.455

Source DB:  PubMed          Journal:  Nagoya J Med Sci        ISSN: 0027-7622            Impact factor:   1.131


  29 in total

Review 1.  Acute and chronic changes of the apparent diffusion coefficient in neurological disorders--biophysical mechanisms and possible underlying histopathology.

Authors:  A Gass; T Niendorf; J G Hirsch
Journal:  J Neurol Sci       Date:  2001-05-01       Impact factor: 3.181

Review 2.  MR diffusion tensor imaging: recent advance and new techniques for diffusion tensor visualization.

Authors:  Yoshitaka Masutani; Shigeki Aoki; Osamu Abe; Naoto Hayashi; Kuni Otomo
Journal:  Eur J Radiol       Date:  2003-04       Impact factor: 3.528

3.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

4.  The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.

Authors:  Betty Soliven; Veronique Miron; Jerold Chun
Journal:  Neurology       Date:  2011-02-22       Impact factor: 9.910

5.  Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Authors:  Ernst-Wilhelm Radue; Paul O'Connor; Chris H Polman; Reinhard Hohlfeld; Peter Calabresi; Krystof Selmaj; Nicole Mueller-Lenke; Catherine Agoropoulou; Frederick Holdbrook; Ana de Vera; Lixin Zhang-Auberson; Gordon Francis; Pascale Burtin; Ludwig Kappos
Journal:  Arch Neurol       Date:  2012-10

6.  Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.

Authors:  R Zivadinov; L Locatelli; D Cookfair; B Srinivasaraghavan; A Bertolotto; M Ukmar; A Bratina; C Maggiore; A Bosco; A Grop; M Catalan; M Zorzon
Journal:  Mult Scler       Date:  2007-02-09       Impact factor: 6.312

Review 7.  FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.

Authors:  Volker Brinkmann
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

8.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

9.  The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat.

Authors:  Nicolas Manel; Derya Unutmaz; Dan R Littman
Journal:  Nat Immunol       Date:  2008-05-04       Impact factor: 25.606

10.  Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients.

Authors:  Emilia Sbardella; Nikolaos Petsas; Francesca Tona; Luca Prosperini; Eytan Raz; Gianvito Pace; Carlo Pozzilli; Patrizia Pantano
Journal:  PLoS One       Date:  2013-05-16       Impact factor: 3.240

View more
  2 in total

Review 1.  The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials.

Authors:  Kedar R Mahajan; Daniel Ontaneda
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

2.  Fingolimod-improved axonal and myelin integrity of white matter tracts associated with multiple sclerosis-related functional impairments.

Authors:  Michael Gurevich; Roy Waknin; Evan Stone; Anat Achiron
Journal:  CNS Neurosci Ther       Date:  2018-01-05       Impact factor: 5.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.